Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnological and biopharmaceutical experts. The company has a pipeline of novel and highly differentiated antibacterial and rare disease product candidates focused on patients' unmet needs with multi-drug resistant (MDR) bacterial infections. 

Biotechnology

Spero Therapeutics

Sath Shukla

Jennifer Marten

Kristyn McCandless

Esther Rajavelu

Ed Sopp

Melissa Stundick

Michael Pucci

Troy Lister

Timothy Keutzer

Thomas Parr

Susan Redican

Shekman Wong

Kathy Burke

Laura McGinn

Nivedita Bhatt

Ilia Terova

Hanna Kwak

Akash Jain

Jamie Brady

Myriah Satterfield

Indu Lakhani

Kamal Hamed

Frank E. Thomas

Tregoning Prior

Scott Jackson

John C. Pottage

David Musselman

Terese Hoekstra

Jay Blackington

Cristina Larkin

The executive team at Spero Therapeutics has a history of experience in the industry, with a focus on health care and medicine. They have also been involved in founding and leading companies such as Synlogic and Rodin Therapeutics. In addition, they have held positions at Cubist Pharmaceuticals and Wyeth.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Spero Therapeutics

Leadership Team

Board of Directors